246 results on '"Vidili, Gianpaolo"'
Search Results
2. ASO Visual Abstract: Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
- Author
-
van Keulen, Anne-Marleen, Buettner, Stefan, Olthof, Pim B., Klümpen, Heinz-Josef, Erdmann, Joris I., Izquierdo-Sanchez, Laura, Banales, Jesus M., Goeppert, Benjamin, Roessler, Stephanie, Zieniewicz, Krzysztof, Lamarca, Angela, Valle, Juan W., La Casta, Adelaida, Hoogwater, Frederik J. H., Donadon, Matteo, Scheiter, Alexander, Marzioni, Marco, Adeva, Jorge, Kiudeliene, Edita, Fernández, Jesús María Urman, Vidili, Gianpaolo, Mocan, Tudor, Fabris, Luca, Krawczyk, Marcin, Folseraas, Trine, Dopazo, Cristina, Detry, Olivier, Voiosu, Theodor, Scripcariu, Viorel, Biancaniello, Francesca, Braconi, Chiara, Macias, Rocio I. R., and Groot Koerkamp, Bas
- Published
- 2024
- Full Text
- View/download PDF
3. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
- Author
-
Zheng, Haixiang, Sechi, Leonardo Antonio, Navarese, Eliano Pio, Casu, Gavino, and Vidili, Gianpaolo
- Published
- 2024
- Full Text
- View/download PDF
4. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma
- Author
-
Cigliano, Antonio, Gigante, Isabella, Serra, Marina, Vidili, Gianpaolo, Simile, Maria M., Steinmann, Sara, Urigo, Francesco, Cossu, Eleonora, Pes, Giovanni M., Dore, Maria P., Ribback, Silvia, Milia, Egle P., Pizzuto, Elena, Mancarella, Serena, Che, Li, Pascale, Rosa M., Giannelli, Gianluigi, Evert, Matthias, Chen, Xin, and Calvisi, Diego F.
- Published
- 2024
- Full Text
- View/download PDF
5. Rate and predictors of thromboprophylaxis in internal medicine wards: Results from the AURELIO study
- Author
-
Filoni, Dario, Totè, Chiara, Trivigno, Chiara, Ciacci, Paolo, Orlando, Federica, Paraninfi, Aurora, Casciaro, Marco Antonio, Accapezzato, Daniele, Rossi, Elisabetta, Gioia, Chiara, Izzo, Raffaella, Summa, Maria Luna, Polisena, Nausica, Iantorno, Laura, Capozza, Alessandro, Marti, Roberta, Meloni, Pier Luigi, Sauchella, Assunta, Melis, Sara, Berria, Maria, Solinas, Beatrice, Vilardi, Luca, Sarobba, Paola, Pisanu, Manuela, Mangatia, Paolo, Armentaro, Giuseppe, Volpentesta, Mara, Scarcelli, Mariarosangela, Cringoli, Maurizio, Blanca, Deborah, Casella, Francesco, Baldini, Lorenzo, Arienti, Vincenzo, Lazzerini, Pietro Enea, Capecchi, Leopoldo, ed Ambra Otranto, Barbara Castignani, Crociani, Andrea, Donnarumma, Emilia, Pacciani, Giulia, Rovereto, Rossella, Lunardi, Sarah, Bonito, Giacomo, Pietrangelo, Antonello, Vegetti, Alberto, Di Minno, Giovanni, Tufano, Antonella, Lodigiani, Corrado, Pacetti, Veronica, Domenicali, Marco, Magna, Arianna, Maggio, Enrico, Vidili, Gianpaolo, Sciacqua, Angela, Cogliati, Chiara, Di Giulio, Rosella, Bernardini, Sciaila, Fallarino, Alessia, Palumbo, Ilaria Maria, Pannunzio, Arianna, Bagnato, Chiara, Serra, Carla, Boddi, Maria, Falsetti, Lorenzo, Zaccone, Vincenzo, Ettorre, Evaristo, Desideri, Giovambattista, Santoro, Luca, Cantisani, Vito, Pignatelli, Pasquale, Santoliquido, Angelo, Violi, Francesco, and Loffredo, Lorenzo
- Published
- 2024
- Full Text
- View/download PDF
6. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care
- Author
-
Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Lani, Lorenzo, Granito, Alessandro, Pelizzaro, Filippo, Cabibbo, Giuseppe, Di Marco, Mariella, Ghittoni, Giorgia, Campani, Claudia, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Giannini, Edoardo G., Biasini, Elisabetta, Saitta, Carlo, Magalotti, Donatella, Sangiovanni, Angelo, Guarino, Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Masotto, Alberto, Sacco, Rodolfo, Vidili, Gianpaolo, Mega, Andrea, Azzaroli, Francesco, Nardone, Gerardo, Brandi, Giovanni, Sabbioni, Simone, Vitale, Alessandro, and Trevisani, Franco
- Published
- 2024
- Full Text
- View/download PDF
7. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis
- Author
-
Roberto Cangemi, Valeria Raparelli, Giovanni Talerico, Stefania Basili, Francesco Violi, Palasciano Giuseppe, D’Alitto Felicia, Palmieri Vincenzo Ostilio, Santovito Daniela, Di Michele Dario, Croce Giuseppe, Sacerdoti David, Brocco Silvia, Fasolato Silvano, Cecchetto Lara, Bombonato Giancarlo, Bertoni Michele, Restuccia Tea, Andreozzi Paola, Liguori Maria Livia, Perticone Francesco, Caroleo Benedetto, Perticone Maria, Staltari Orietta, Manfredini Roberto, De Giorgi Alfredo, Averna Maurizio, Giammanco Antonina, Granito Alessandro, Pettinari Irene, Marinelli Sara, Bolondi Luigi, Falsetti Lorenzo, Salvi Aldo, Durante-Mangoni Emanuele, Cesaro Flavio, Farinaro Vincenza, Ragone Enrico, Morana Ignazio, Andriulli Angelo, Ippolito Antonio, Iacobellis Angelo, Niro Grazia, Merla Antonio, Raimondo Giovanni, Maimone Sergio, Cacciola Irene, Varvara Doriana, Drenaggi Davide, Staffolani Silvia, Picardi Antonio, Vespasiani-Gentilucci Umberto, Galati Giovanni, Gallo Paolo, Davì Giovanni, Schiavone Cosima, Santilli Francesca, Tana Claudio, Licata Anna, Soresi Maurizio, Bianchi Giovanni Battista, Carderi Isabella, Pinto Antonio, Tuttolomondo Antonino, Ferrari Giovanni, Gresele Paolo, Fierro Tiziana, Morelli Olivia, Laffi Giacomo, Romanelli Roberto Giulio, Arena Umberto, Stasi Cristina, Gasbarrini Antonio, Gargovich Matteo, Zocco Maria Assunta, Riccardi Laura, Ainora Maria Elena, Capeci William, Martino Giuseppe Pio, Nobili Lorenzo, Cavallo Maurizio, Frugiuele Pierluigi, Greco Antonio, Pietrangelo Antonello, Ventura Paolo, Cuoghi Chiara, Marcacci Matteo, Serviddio Gaetano, Vendemiale Gianluigi, Villani Rosanna, Gargano Ruggiero, Vidili Gianpaolo, Di Cesare Valentina, Masala Maristella, Delitala Giuseppe, Invernizzi Pietro, Di Minno Giovanni, Tufano Antonella, Purrello Francesco, Privitera Graziella, Forgione Alessandra, Curigliano Valentina, Senzolo Marco, Rodríguez-Castro Kryssia Isabel, Giannelli Gianluigi, Serra Carla, Neri Sergio, Pignataro Pietro, Rizzetto Mario, Debernardi Venon Wilma, Svegliati Baroni Gianluca, Bergamaschi Gaetano, Masotti Michela, Costanzo Filippo, Corazza Gino Roberto, Caldwell Stephen Hugh, Angelico Francesco, Del Ben Maria, Napoleone Laura, Polimeni Licia, Proietti Marco, Raparelli Valeria, Romiti Giulio Francesco, Ruscio Eleonora, Severoni Andrea, Talerico Giovanni, Toriello Filippo, and Vestri Annarita
- Subjects
Albumin ,Cirrhosis ,Portal Vein Thrombosis ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background and Aims: Hypoalbuminemia, as defined by serum albumin (SA) levels ≤35 g/L, is associated to venous and arterial thrombosis in general population and in patients at risk of cardiovascular disease. It is unknown if SA ≤35 g/L is also associated to portal vein thrombosis (PVT) in cirrhosis. Methods: Cirrhotic patients enrolled in the Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry (PRO-LIVER) study (n = 753), were followed-up for 2 years to assess the risk of PVT, that was diagnosed by Doppler ultrasonography. Child-Pugh classes, Model for End-Stage Liver Disease score, presence of hepatocellular carcinoma and laboratory variables including SA, D-dimer, and high-sensitivity C-reactive protein (hs-CRP) were measured at baseline. Results: SA ≤35 g/L was detected in 52% of patients. A logistic multivariate regression analysis showed that higher Child-Pugh class, hepatocellular carcinoma and thrombocytopenia were significantly associated to SA ≤35 g/L. In a subgroup of patients where data regarding hs-CRP and D-dimer were available, SA ≤35 g/L was inversely associated with hs-CRP and D-dimer. During the follow-up, a total of 61 patients experienced PVT. A Kaplan Meier survival analysis showed SA ≤35 g/L was associated to increased risk of PVT compared to SA >35 g/L (P = .005). A multivariate Cox proportional hazards regression analysis showed that male sex, lower platelet count, and SA ≤35 g/L remained associated to PVT after adjusting for confounding factors. Conclusion: Cirrhotic patients with SA ≤35 g/L are at higher risk of experiencing PVT compared to those with SA >35 g/L and could be considered as potential candidates to anticoagulant prophylaxis for PVT prevention.
- Published
- 2024
- Full Text
- View/download PDF
8. SIUMB recommendations on the use of ultrasound in neoplastic lesions of the gallbladder and extrahepatic biliary tract
- Author
-
de Sio, Ilario, D’Onofrio, Mirko, Mirk, Paoletta, Bertolotto, Michele, Priadko, Kateryna, Schiavone, Cosima, Cantisani, Vito, Iannetti, Giovanni, Vallone, Gianfranco, and Vidili, Gianpaolo
- Published
- 2023
- Full Text
- View/download PDF
9. An ultrasound-based approach to jaundice from diagnosis to treatment
- Author
-
Vidili, Gianpaolo, Arru, Marco, Solinas, Beatrice, and Turilli, Davide
- Published
- 2023
- Full Text
- View/download PDF
10. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
- Author
-
Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Allegrini, Gloria, Cammà, Calogero, Cabibbo, Giuseppe, Giacchetto, Carmelo Marco, Giuffrida, Paolo, Grassini, Maria Vittoria, Grova, Mauro, Rancatore, Gabriele, Stornello, Caterina, Adotti, Valentina, Cavoli, Tancredi Li, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Napoli, Lucia, Conti, Fabio, Frassineti, G.L., Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Missale, Gabriele, Olivani, Andrea, Capasso, Mario, Cossiga, Valentina, Guarino, Maria, Marina Cela, Ester, Facciorusso, Antonio, Graziosi, Camilla, Lauria, Valentina, Pelecca, Giorgio, Schirripa, Marta, Chegai, Fabrizio, Raso, Armando, Bozzi, Alessio, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Plaz Torres, Maria Corina, Pieri, Giulia, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Reggidori, Nicola, Bucci, Laura, Santi, Valentina, Stefanini, Benedetta, Lani, Lorenzo, Rampoldi, Davide, Ghittoni, Giorgia, Farinati, Fabio, Masotto, Alberto, Stefanini, Bernardo, Mega, Andrea, Biasini, Elisabetta, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Sangiovanni, Angelo, Campani, Claudia, Raimondo, Giovanni, Vidili, Gianpaolo, Gasbarrini, Antonio, Celsa, Ciro, Di Marco, Mariella, Giannini, Edoardo G., Sacco, Rodolfo, Brunetto, Maurizia Rossana, Azzaroli, Francesco, Magalotti, Donatella, Morisco, Filomena, Rapaccini, Gian Ludovico, Nardone, Gerardo, Vitale, Alessandro, and Trevisani, Franco
- Published
- 2023
- Full Text
- View/download PDF
11. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
- Author
-
Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Bertellini, Federica, Farinati, Fabio, Palano, Giorgio, Pelizzaro, Filippo, Penzo, Barbara, Pinto, Elisa, Allegrini, Gloria, Cammà, Calogero, Celsa, Ciro, Giuffrida, Paolo, Stornello, Caterina, Grova, Mauro, Giacchetto, Carmelo Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, Adotti, Valentina, Gitto, Stefano, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Napoli, Lucia, Domenicali, Marco, Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Olivani, Andrea, Missale, Gabriele, Cossiga, Valentina, Capasso, Mario, Morisco, Filomena, Cela, Ester Marina, Facciorusso, Antonio, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Giannini, Edoardo G., Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria, Sangiovanni, Angelo, and Trevisani, Franco
- Published
- 2022
- Full Text
- View/download PDF
12. Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications
- Author
-
Loffredo, Lorenzo, Vidili, Gianpaolo, Sciacqua, Angela, Cogliati, Chiara, Di Giulio, Rosella, Bernardini, Sciaila, Ciacci, Paolo, Pietrangelo, Antonello, Orlando, Federica, Paraninfi, Aurora, Boddi, Maria, Di Minno, Giovanni, Falsetti, Lorenzo, Lodigiani, Corrado, Santoliquido, Angelo, Ettorre, Evaristo, Pignatelli, Pasquale, Arezzo, Maria Felice, Gutu, Evghenii, Harenberg, Job, and Violi, Francesco
- Published
- 2022
- Full Text
- View/download PDF
13. Microplastics and nanoplastics in cardiovascular disease--a narrative review with worrying links.
- Author
-
Haixiang Zheng, Vidili, Gianpaolo, Casu, Gavino, Navarese, Eliano Pio, Sechi, Leonardo A., and Youren Chen
- Subjects
POISONS ,CARDIOVASCULAR system ,PLASTICS ,POLLUTION ,MYOCARDIAL infarction - Abstract
With the widespread use of plastic products and the increase in waste, microplastics and nanoplastics (MNPs) have become an important issue in global environmental pollution. In recent years, an increasing number of studies have shown that MNPs may have negative impacts on human health. This review aimed to explore the association between MNPs and cardiovascular disease and provide an outlook for future research. Research has shown that there may be a link between MNPs exposure and cardiovascular disease. Laboratory studies have shown that animals exposed to MNPs often exhibit abnormalities in the cardiovascular system, such as increased blood pressure, vascular inflammation, and myocardial damage. Epidemiological surveys have also revealed that people exposed to MNPs are more likely to suffer from cardiovascular diseases, such as hypertension and myocardial infarction. Although the specific impact mechanism is not fully understood, there are several possible pathways of action, including the effects of toxic substances on MNPs and interference with the endocrine system. In summary, MNPs exposure may have a negative impact on cardiovascular health, but further research is needed to confirm its specific mechanism and extent of impact to guide relevant public health and environmental policies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
- Author
-
Zhang, Shanshan, Song, Xinhua, Cao, Dan, Xu, Zhong, Fan, Biao, Che, Li, Hu, Junjie, Chen, Bin, Dong, Mingjie, Pilo, Maria G, Cigliano, Antonio, Evert, Katja, Ribback, Silvia, Dombrowski, Frank, Pascale, Rosa M, Cossu, Antonio, Vidili, Gianpaolo, Porcu, Alberto, Simile, Maria M, Pes, Giovanni M, Giannelli, Gianluigi, Gordan, John, Wei, Lixin, Evert, Matthias, Cong, Wenming, Calvisi, Diego F, and Chen, Xin
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Liver Disease ,Stem Cell Research ,Prevention ,Cancer ,Digestive Diseases ,Digestive Diseases - (Gallbladder) ,Stem Cell Research - Nonembryonic - Non-Human ,Rare Diseases ,Liver Cancer ,Adaptor Proteins ,Signal Transducing ,Animals ,Antineoplastic Agents ,Bile Duct Neoplasms ,Cell Cycle Proteins ,Cholangiocarcinoma ,Female ,Humans ,Mechanistic Target of Rapamycin Complex 1 ,Mechanistic Target of Rapamycin Complex 2 ,Mice ,Phosphoproteins ,Protein Kinase Inhibitors ,Proto-Oncogene Proteins c-akt ,Signal Transduction ,TOR Serine-Threonine Kinases ,YAP-Signaling Proteins ,Intrahepatic cholangiocarcinoma ,Dual mTOR inhibitor ,Targeted therapy ,Gemcitabine ,Translational medicine ,Mouse model ,MLN0128 ,Public Health and Health Services ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background & aimsIntrahepatic cholangiocarcinoma (ICC) is a lethal malignancy without effective treatment options. MLN0128, a second generation pan-mTOR inhibitor, shows efficacy for multiple tumor types. We evaluated the therapeutic potential of MLN0128 vs. gemcitabine/oxaliplatin in a novel ICC mouse model.MethodsWe established a novel ICC mouse model via hydrodynamic transfection of activated forms of AKT (myr-AKT) and Yap (YapS127A) protooncogenes (that will be referred to as AKT/YapS127A). Genetic approaches were applied to study the requirement of mTORC1 and mTORC2 in mediating AKT/YapS127A driven tumorigenesis. Gemcitabine/oxaliplatin and MLN0128 were administered in AKT/YapS127A tumor-bearing mice to study their anti-tumor efficacy in vivo. Multiple human ICC cell lines were used for in vitro experiments. Hematoxylin and eosin staining, immunohistochemistry and immunoblotting were applied for the characterization and mechanistic study.ResultsCo-expression of myr-AKT and YapS127A promoted ICC development in mice. Both mTORC1 and mTORC2 complexes were required for AKT/YapS127A ICC development. Gemcitabine/oxaliplatin had limited efficacy in treating late stage AKT/YapS127A ICC. In contrast, partial tumor regression was achieved when MLN0128 was applied in the late stage of AKT/YapS127A cholangiocarcinogenesis. Furthermore, when MLN0128 was administered in the early stage of AKT/YapS127A carcinogenesis, it led to disease stabilization. Mechanistically, MLN0128 efficiently inhibited AKT/mTOR signaling both in vivo and in vitro, inducing strong ICC cell apoptosis and only marginally affecting proliferation.ConclusionsThis study suggests that mTOR kinase inhibitors may be beneficial for the treatment of ICC, even in tumors that are resistant to standard of care chemotherapeutics, such as gemcitabine/oxaliplatin-based regimens, especially in the subset of tumors exhibiting activated AKT/mTOR cascade. Lay summary: We established a novel mouse model of intrahepatic cholangiocarcinoma (ICC). Using this new preclinical model, we evaluated the therapeutic potential of mTOR inhibitor MLN0128 vs. gemcitabine/oxaliplatin (the standard chemotherapy for ICC treatment). Our study shows the anti-neoplastic potential of MLN0128, suggesting that it may be superior to gemcitabine/oxaliplatin-based chemotherapy for the treatment of ICC, especially in the tumors exhibiting activated AKT/mTOR cascade.
- Published
- 2017
15. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
- Author
-
Marasco, Giovanni, Colecchia, Antonio, Bacchi Reggiani, Maria Letizia, Celsa, Ciro, Farinati, Fabio, Giannini, Edoardo Giovanni, Benevento, Francesca, Rapaccini, Gian Ludovico, Caturelli, Eugenio, Di Marco, Mariella, Biasini, Elisabetta, Marra, Fabio, Morisco, Filomena, Foschi, Francesco Giuseppe, Zoli, Marco, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Masotto, Alberto, Sacco, Rodolfo, Raimondo, Giovanni, Azzaroli, Francesco, Mega, Andrea, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Dajti, Elton, Ravaioli, Federico, Avanzato, Francesca, Festi, Davide, and Trevisani, Franco
- Published
- 2021
- Full Text
- View/download PDF
16. Clinical history of cancer‐associated splanchnic vein thrombosis
- Author
-
Valeriani, Emanuele, Di Nisio, Marcello, Riva, Nicoletta, Caiano, Lucia Maria, Porreca, Ettore, Bang, Soo‐Mee, Beyer‐Westendorf, Jan, Sartori, Maria Teresa, Barillari, Giovanni, Santoro, Rita, Kamphuisen, Pieter W., Alatri, Adriano, Malato, Alessandra, Vidili, Gianpaolo, Oh, Doyeun, Schulman, Sam, and Ageno, Walter
- Published
- 2021
- Full Text
- View/download PDF
17. Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis
- Author
-
Cigliano, Antonio, Pilo, Maria G, Li, Lei, Latte, Gavinella, Szydlowska, Marta, Simile, Maria M, Paliogiannis, Panagiotis, Che, Li, Pes, Giovanni M, Palmieri, Giuseppe, Sini, Maria C, Cossu, Antonio, Porcu, Alberto, Vidili, Gianpaolo, Seddaiu, Maria A, Pascale, Rosa M, Ribback, Silvia, Dombrowski, Frank, Chen, Xin, and Calvisi, Diego F
- Subjects
Liver Disease ,Rare Diseases ,Genetics ,Cancer ,Biotechnology ,Liver Cancer ,Digestive Diseases ,Aetiology ,2.1 Biological and endogenous factors ,hepatocellular carcinoma ,liver cancer ,HSF1 ,c-Myc ,signalling pathways ,Oncology and Carcinogenesis - Abstract
Deregulated activity of the c-Myc protooncogene is a frequent molecular event underlying mouse and human hepatocarcinogenesis. Nonetheless, the mechanisms sustaining c-Myc oncogenic activity in liver cancer remain scarcely delineated. Recently, we showed that the mammalian target of rapamycin complex 1 (mTORC1) cascade is induced and necessary for c-Myc dependent liver tumor development and progression. Since the heat shock factor 1 (HSF1) transcription factor is a major positive regulator of mTORC1 in the cell, we investigated the functional interaction between HSF1 and c-Myc using in vitro and in vivo approaches. We found that ablation of HSF1 restrains the growth of c-Myc-derived mouse hepatocellular carcinoma (HCC) cell lines, where it induces downregulation of c-Myc levels. Conversely, silencing of c-Myc gene in human and mouse HCC cells led to downregulation of HSF1 expression. Most importantly, overexpression of a dominant negative form of HSF1 (HSF1dn) in the mouse liver via hydrodynamic gene delivery resulted in the complete inhibition of mouse hepatocarcinogenesis driven by overexpression of c-Myc. Altogether, the present results indicate that a functional HSF1 is necessary for c-Myc-driven hepatocarcinogenesis. Consequently, targeting HSF1 might represent a novel and effective therapeutic strategy for the treatment of HCC subsets with activated c-Myc signaling.
- Published
- 2017
18. Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice
- Author
-
Cigliano, Antonio, Wang, Chunmei, Pilo, Maria G, Szydlowska, Marta, Brozzetti, Stefania, Latte, Gavinella, Pes, Giovanni M, Pascale, Rosa M, Seddaiu, Maria A, Vidili, Gianpaolo, Ribback, Silvia, Dombrowski, Frank, Evert, Matthias, Chen, Xin, and Calvisi, Diego F
- Subjects
Digestive Diseases ,Biotechnology ,Genetics ,Rare Diseases ,Liver Disease ,Orphan Drug ,Cancer ,Liver Cancer ,2.1 Biological and endogenous factors ,Aetiology ,hepatocellular carcinoma ,HSF1 ,signaling pathways ,Oncology and Carcinogenesis - Abstract
Upregulation of the heat shock transcription factor 1 (HSF1) has been described as a frequent event in many cancer types, but its oncogenic role in hepatocellular carcinoma (HCC) remains poorly delineated. In the present study, we assessed the function(s) of HSF1 in hepatocarcinogenesis via in vitro and in vivo approaches. In particular, we determined the importance of HSF1 on v-Akt murine thymoma viral oncogene homolog (AKT)-induced liver cancer development in mice. We found that knockdown of HSF1 activity via specific siRNA triggered growth restraint by suppressing cell proliferation and inducing massive cell apoptosis in human HCC cell lines. At the molecular level, HSF1 inhibition was accompanied by downregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) cascade and related metabolic pathways. Most importantly, overexpression of a dominant negative form of HSF1 (HSF1dn) in the mouse liver via hydrodynamic gene delivery led to the inhibition of mouse hepatocarcinogenesis driven by overexpression of AKT. In human liver cancer specimens, we detected that HSF1 is progressively induced from human non-tumorous surrounding livers to HCC, reaching the highest expression in the tumors characterized by the poorest outcome (as defined by the length of patients' survival). In conclusion, HSF1 is an independent prognostic factor in liver cancer and might represent an innovative therapeutic target in HCC subsets characterized by activation of the AKT/mTOR pathway.
- Published
- 2017
19. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c‐Myc‐driven hepatocarcinogenesis
- Author
-
Liu, Pin, Ge, Mengmeng, Hu, Junjie, Li, Xiaolei, Che, Li, Sun, Kun, Cheng, Lili, Huang, Yuedong, Pilo, Maria G, Cigliano, Antonio, Pes, Giovanni M, Pascale, Rosa M, Brozzetti, Stefania, Vidili, Gianpaolo, Porcu, Alberto, Cossu, Antonio, Palmieri, Giuseppe, Sini, Maria C, Ribback, Silvia, Dombrowski, Frank, Tao, Junyan, Calvisi, Diego F, Chen, Ligong, and Chen, Xin
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Cancer ,Liver Disease ,Liver Cancer ,Digestive Diseases ,Genetics ,Rare Diseases ,2.1 Biological and endogenous factors ,Aetiology ,Adaptor Proteins ,Signal Transducing ,Animals ,Apoptosis ,Biopsy ,Needle ,Carcinogenesis ,Carcinoma ,Hepatocellular ,Cell Cycle Proteins ,Disease Models ,Animal ,Genes ,myc ,Humans ,Immunohistochemistry ,Kaplan-Meier Estimate ,Liver Neoplasms ,Mechanistic Target of Rapamycin Complex 1 ,Mice ,Mice ,Knockout ,Multiprotein Complexes ,Phosphoproteins ,Phosphorylation ,Proportional Hazards Models ,Proto-Oncogene Mas ,Random Allocation ,Signal Transduction ,Sirolimus ,Statistics ,Nonparametric ,TOR Serine-Threonine Kinases ,Medical Biochemistry and Metabolomics ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Amplification and/or activation of the c-Myc proto-oncogene is one of the leading genetic events along hepatocarcinogenesis. The oncogenic potential of c-Myc has been proven experimentally by the finding that its overexpression in the mouse liver triggers tumor formation. However, the molecular mechanism whereby c-Myc exerts its oncogenic activity in the liver remains poorly understood. Here, we demonstrate that the mammalian target of rapamycin complex 1 (mTORC1) cascade is activated and necessary for c-Myc-dependent hepatocarcinogenesis. Specifically, we found that ablation of Raptor, the unique member of mTORC1, strongly inhibits c-Myc liver tumor formation. Also, the p70 ribosomal S6 kinase/ribosomal protein S6 and eukaryotic translation initiation factor 4E-binding protein 1/eukaryotic translation initiation factor 4E signaling cascades downstream of mTORC1 are required for c-Myc-driven tumorigenesis. Intriguingly, microarray expression analysis revealed up-regulation of multiple amino acid transporters, including solute carrier family 1 member A5 (SLC1A5) and SLC7A6, leading to robust uptake of amino acids, including glutamine, into c-Myc tumor cells. Subsequent functional studies showed that amino acids are critical for activation of mTORC1 as their inhibition suppressed mTORC1 in c-Myc tumor cells. In human hepatocellular carcinoma specimens, levels of c-Myc directly correlate with those of mTORC1 activation as well as of SLC1A5 and SLC7A6.ConclusionOur current study indicates that an intact mTORC1 axis is required for c-Myc-driven hepatocarcinogenesis; thus, targeting the mTOR pathway or amino acid transporters may be an effective and novel therapeutic option for the treatment of hepatocellular carcinoma with activated c-Myc signaling. (Hepatology 2017;66:167-181).
- Published
- 2017
20. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells
- Author
-
Cao, Dan, Song, Xinhua, Che, Li, Li, Xiaolei, Pilo, Maria G, Vidili, Gianpaolo, Porcu, Alberto, Solinas, Antonio, Cigliano, Antonio, Pes, Giovanni M, Ribback, Silvia, Dombrowski, Frank, Chen, Xin, Li, Lei, and Calvisi, Diego F
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Liver Disease ,Cancer ,Liver Cancer ,Rare Diseases ,Digestive Diseases ,Animals ,Carcinoma ,Hepatocellular ,Cell Line ,Tumor ,Cell Proliferation ,Fatty Acid Synthase ,Type I ,Fatty Acids ,Humans ,Lipoprotein Lipase ,Liver Neoplasms ,Mice ,Multivariate Analysis ,Proportional Hazards Models ,RNA ,Small Interfering ,Signal Transduction ,Triglycerides ,Up-Regulation ,fatty acid synthase ,hepatocellular carcinoma ,lipogenesis ,lipoprotein lipase ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background & aimsAlthough it is well established that fatty acids (FA) are indispensable for the proliferation and survival of cancer cells in hepatocellular carcinoma (HCC), inhibition of Fatty Acid Synthase (FASN) cannot completely repress HCC cell growth in culture. Thus, we hypothesized that uptake of exogenous FA by cancer cells might play an important role in the development and progression of HCC. Lipoprotein lipase (LPL) is the enzyme that catalyses the hydrolysis of triglycerides into free fatty acids (FFA) and increases the cellular uptake of FA.MethodsWe used immunohistochemistry and quantitative reverse transcription real-time polymerase chain reaction to evaluate LPL expression in human and mouse HCC samples. Using lipoprotein-deficient medium as well as siRNAs against LPL and/or FASN, we investigated whether human HCC cells depend on both endogenous and exogenous fatty acids for survival in vitro.ResultsWe found that LPL is upregulated in mouse and human HCC samples. High expression of LPL in human HCC samples is associated with poor prognosis. In HCC cell lines, silencing of FASN or LPL or culturing the cells in lipoprotein-deficient medium significantly decreased cell proliferation. Importantly, when FASN suppression was coupled to concomitant LPL depletion, the growth restraint of cell lines was further augmented.ConclusionsThe present study strongly suggests that both de novo synthetized and exogenous FA play a major role along hepatocarcinogenesis. Thus, combined suppression of LPL and FASN might be highly beneficial for the treatment of human HCC.
- Published
- 2017
21. Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma.
- Author
-
Vitale, Alessandro, Romano, Pierluigi, Cillo, Umberto, Lauterio, Andrea, Sangiovanni, Angelo, Cabibbo, Giuseppe, Missale, Gabriele, Marseglia, Mariarosaria, Trevisani, Franco, Foschi, Francesco Giuseppe, Cipriani, Federica, Famularo, Simone, Marra, Fabio, Saitta, Carlo, Serenari, Matteo, Vidili, Gianpaolo, Morisco, Filomena, Caturelli, Eugenio, Mega, Andrea, and Pelizzaro, Filippo
- Published
- 2024
- Full Text
- View/download PDF
22. Comparison of 2D Shear Wave Elastography and Transient Elastography in Non-Invasive Evaluation of Liver Fibrosis in Hepatitis C Virus-Related Chronic Liver Disease.
- Author
-
Vidili, Gianpaolo, Arru, Marco, Meloni, Pierluigi, Solinas, Giuliana, Atzori, Sebastiana, and Maida, Ivana
- Subjects
- *
HEPATIC fibrosis , *CHRONIC hepatitis C , *SHEAR waves , *LIVER diseases , *RECEIVER operating characteristic curves - Abstract
Background: Transient Elastography (TE) is widely regarded as the most reliable non-invasive method for evaluating liver fibrosis. Recently, new techniques such as 2D Shear Wave Elastography (2D-SWE) have been developed. This study aimed to evaluate the correlation between TE and 2D-SWE in patients with HCV-related chronic liver disease and to redefine the cut-off values of 2D-SWE for predicting different stages of fibrosis based on our results. Methods: Both TE (Fibroscan, Echosens, Paris, France) and 2D-SWE (SuperSonic Imagine) were performed simultaneously in 170 patients, including those with active and eradicated HCV infection. Spearman's rank correlation coefficient was used to assess the correlation between the two measurements, and the concordance between the assigned METAVIR classes was calculated using Cohen's kappa coefficient. ROC curves were constructed to determine the optimal cut-off values for 2D-SWE. Results: Ten patients were excluded for invalid measurements. In the remaining 160 patients, TE and 2D-SWE demonstrated a high correlation (ρ = 0.83, p < 0.0001) and good agreement in METAVIR classification (k = 0.74). The optimal cut-off values identified for 2D-SWE were as follows: ≥ 7 kPa for F ≥ 2, ≥ 8.3 kPa for F ≥ 3, and ≥ 9.4 kPa for F4. Conclusions: 2D-SWE is a viable alternative to TE for patients with HCV-related chronic liver disease. Our data suggest that the currently accepted 2D-SWE cut-off values for cirrhosis (F4) should be reconsidered and potentially lowered. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27 KIP1 Regulation.
- Author
-
Cigliano, Antonio, Simile, Maria M., Vidili, Gianpaolo, Pes, Giovanni M., Dore, Maria P., Urigo, Francesco, Cossu, Eleonora, Che, Li, Feo, Claudio, Steinmann, Sara M., Ribback, Silvia, Pascale, Rosa M., Evert, Matthias, Chen, Xin, and Calvisi, Diego F.
- Subjects
FATTY acid synthases ,HEPATOCELLULAR carcinoma ,SMALL interfering RNA ,LIVER cancer ,LIVER tumors ,PROTEIN kinases - Abstract
Background and Objectives: Aberrant upregulation of fatty acid synthase (FASN), catalyzing de novo synthesis of fatty acids, occurs in various tumor types, including human hepatocellular carcinoma (HCC). Although FASN oncogenic activity seems to reside in its pro-lipogenic function, cumulating evidence suggests that FASN's tumor-supporting role might also be metabolic-independent. Materials and Methods: In the present study, we show that FASN inactivation by specific small interfering RNA (siRNA) promoted the downregulation of the S-phase kinase associated-protein kinase 2 (SKP2) and the consequent induction of p27
KIP1 in HCC cell lines. Results: Expression levels of FASN and SKP2 directly correlated in human HCC specimens and predicted a dismal outcome. In addition, forced overexpression of SKP2 rendered HCC cells resistant to the treatment with the FASN inhibitor C75. Furthermore, FASN deletion was paralleled by SKP2 downregulation and p27KIP1 induction in the AKT-driven HCC preclinical mouse model. Moreover, forced overexpression of an SKP2 dominant negative form or a p27KIP1 non-phosphorylatable (p27KIP1-T187A ) construct completely abolished AKT-dependent hepatocarcinogenesis in vitro and in vivo. Conclusions: In conclusion, the present data indicate that SKP2 is a critical downstream effector of FASN and AKT-dependent hepatocarcinogenesis in liver cancer, envisaging the possibility of effectively targeting FASN-positive liver tumors with SKP2 inhibitors or p27KIP1 activators. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
24. Effect of Probiotic Use on Adverse Events in Adult Patients with Inflammatory Bowel Disease: a Retrospective Cohort Study
- Author
-
Dore, Maria Pina, Rocchi, Chiara, Longo, Nunzio Pio, Scanu, Antonio Mario, Vidili, Gianpaolo, Padedda, Federica, and Pes, Giovanni Mario
- Published
- 2020
- Full Text
- View/download PDF
25. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: A cross-sectional controlled study with real-time two-dimensional shear wave elastography
- Author
-
Erre, Gian Luca, Cadoni, Maria Luisa, Meloni, Pierluigi, Castagna, Floriana, Mangoni, Arduino Aleksander, Piga, Matteo, Passiu, Giuseppe, Carru, Ciriaco, Zinellu, Angelo, and Vidili, Gianpaolo
- Published
- 2019
- Full Text
- View/download PDF
26. Red Cell Distribution Width as a Predictor of Survival in Patients with Hepatocellular Carcinoma.
- Author
-
Vidili, Gianpaolo, Zinellu, Angelo, Mangoni, Arduino Aleksander, Arru, Marco, De Murtas, Valentina, Cuccuru, Elena, Fancellu, Alessandro, and Paliogiannis, Panagiotis
- Subjects
OVERALL survival ,ERYTHROCYTES ,BILIARY tract cancer ,BODY mass index ,MULTIVARIATE analysis ,GALLBLADDER cancer ,HEPATOCELLULAR carcinoma - Abstract
Background and Objectives. Hepatocellular carcinoma (HCC) and the intrahepatic biliary tract cancers are estimated to rank sixth for incidence among solid cancers worldwide, and third for mortality rates. A critical issue remains the need for accurate biomarkers for risk stratification and overall prognosis. The aim of this study was to investigate the ability of a biomarker of heterogeneity of the size of red blood cells, the red cell distribution width (RDW), to predict survival in patients with HCC. Materials and Methods. A consecutive series of patients with a histologic diagnosis of HCC were included into this study irrespective of their age, stage of the disease, and treatment administered, and followed-up for a period of three years. Demographic, anthropometric [age, sex, body mass index (BMI)], and clinical data (Charlson Comorbidity Index, Child–Pugh score, etc.), along with laboratory tests were retrieved from clinical records. Results. One-hundred and four patients were included in this study. Among them, 54 (69%) were deceased at the end of the follow-up. Higher RDW values, but not other hematological and biochemical parameters, were significantly associated with mortality in both univariate and multivariate analysis. The optimal RDW cut-off value identified with the Youden test for survival was 14.7%, with 65% sensitivity and 74% specificity (AUC = 0.718, 95% CI 0.622–0.802, p < 0.001). Kaplan–Meier survival curves showed significantly lower survival with higher RDW values (HR = 3.5204; 95% CI 1.9680–6.2975, p < 0.0001) with a mean survival of 30.9 ± 9.67 months for patients with RDW ≤ 14.7% and 22.3 ± 11.4 months for patients with RDW > 14.7%. Conclusions. The results of our study showed that RDW can perform better than other blood-based biomarkers in independently predicting prognosis in patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Common Variable Immunodeficiency and Selective IgA Deficiency: Focus on Autoimmune Manifestations and Their Pathogenesis
- Author
-
Sircana, Marta Chiara, primary, Vidili, Gianpaolo, additional, Gidaro, Antonio, additional, Delitala, Alessandro Palmerio, additional, Filigheddu, Fabiana, additional, Castelli, Roberto, additional, and Manetti, Roberto, additional
- Published
- 2023
- Full Text
- View/download PDF
28. Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience
- Author
-
Garcovich, Matteo, Faccia, Mariella, Meloni, Franca, Bertolini, Emanuela, de Sio, Ilario, Calabria, Giosuele, Francica, Giampiero, Vidili, Gianpaolo, Riccardi, Laura, Zocco, Maria Assunta, Ainora, Maria Elena, Ponziani, Francesca Romana, De Gaetano, Anna Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, and Pompili, Maurizio
- Published
- 2019
- Full Text
- View/download PDF
29. SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease
- Author
-
Vidili, Gianpaolo, De Sio, Ilario, D’Onofrio, Mirko, Mirk, Paoletta, Bertolotto, Michele, Schiavone, Cosima, and The SIUMB experts committee
- Published
- 2019
- Full Text
- View/download PDF
30. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
- Author
-
Reggidori, Nicola, primary, Bucci, Laura, additional, Santi, Valentina, additional, Stefanini, Benedetta, additional, Lani, Lorenzo, additional, Rampoldi, Davide, additional, Ghittoni, Giorgia, additional, Farinati, Fabio, additional, Masotto, Alberto, additional, Stefanini, Bernardo, additional, Mega, Andrea, additional, Biasini, Elisabetta, additional, Foschi, Francesco Giuseppe, additional, Svegliati-Baroni, Gianluca, additional, Sangiovanni, Angelo, additional, Campani, Claudia, additional, Raimondo, Giovanni, additional, Vidili, Gianpaolo, additional, Gasbarrini, Antonio, additional, Celsa, Ciro, additional, Di Marco, Mariella, additional, Giannini, Edoardo G., additional, Sacco, Rodolfo, additional, Brunetto, Maurizia Rossana, additional, Azzaroli, Francesco, additional, Magalotti, Donatella, additional, Morisco, Filomena, additional, Rapaccini, Gian Ludovico, additional, Nardone, Gerardo, additional, Vitale, Alessandro, additional, Trevisani, Franco, additional, Biselli, Maurizio, additional, Caraceni, Paolo, additional, Gramenzi, Annagiulia, additional, Benevento, Francesca, additional, Granito, Alessandro, additional, Muratori, Luca, additional, Piscaglia, Fabio, additional, Tovoli, Francesco, additional, Allegrini, Gloria, additional, Cammà, Calogero, additional, Cabibbo, Giuseppe, additional, Giacchetto, Carmelo Marco, additional, Giuffrida, Paolo, additional, Grassini, Maria Vittoria, additional, Grova, Mauro, additional, Rancatore, Gabriele, additional, Stornello, Caterina, additional, Adotti, Valentina, additional, Cavoli, Tancredi Li, additional, Marra, Fabio, additional, Rosi, Martina, additional, Bevilacqua, Vittoria, additional, Borghi, Alberto, additional, Napoli, Lucia, additional, Conti, Fabio, additional, Frassineti, G.L., additional, Migliano, Maria Teresa, additional, de Matthaeis, Nicoletta, additional, Ponziani, Francesca Romana, additional, Missale, Gabriele, additional, Olivani, Andrea, additional, Capasso, Mario, additional, Cossiga, Valentina, additional, Guarino, Maria, additional, Marina Cela, Ester, additional, Facciorusso, Antonio, additional, Graziosi, Camilla, additional, Lauria, Valentina, additional, Pelecca, Giorgio, additional, Schirripa, Marta, additional, Chegai, Fabrizio, additional, Raso, Armando, additional, Bozzi, Alessio, additional, Franzè, Maria Stella, additional, Saitta, Carlo, additional, Sauchella, Assunta, additional, Dajti, Elton, additional, Ravaioli, Federico, additional, Plaz Torres, Maria Corina, additional, Pieri, Giulia, additional, Oliveri, Filippo, additional, Ricco, Gabriele, additional, Romagnoli, Veronica, additional, Inno, Alessandro, additional, Marchetti, Fabiana, additional, Coccoli, Pietro, additional, Malerba, Antonio, additional, Cappelli, Alberta, additional, Golfieri, Rita, additional, Mosconi, Cristina, additional, and Renzulli, Matteo, additional
- Published
- 2023
- Full Text
- View/download PDF
31. Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.
- Author
-
Pelizzaro, Filippo, Trevisani, Franco, Simeon, Vittorio, Vitale, Alessandro, Cillo, Umberto, Piscaglia, Fabio, Missale, Gabriele, Sangiovanni, Angelo, Foschi, Francesco G., Cabibbo, Giuseppe, Caturelli, Eugenio, Di Marco, Maria, Azzaroli, Francesco, Brunetto, Maurizia R., Raimondo, Giovanni, Vidili, Gianpaolo, Guarino, Maria, Gasbarrini, Antonio, Campani, Claudia, and Svegliati‐Baroni, Gianluca
- Subjects
LIVER cancer ,LIVER ,OVERALL survival ,DISEASE relapse ,DATABASES - Abstract
Background and Aims: Hepatocellular carcinoma (HCC) recurrence is common in patients treated with liver resection (LR). In this study, we aimed to evaluate the incidence and preoperative predictors of non‐transplantable recurrence in patients with single HCC ≤5 cm treated with frontline LR. Methods: From the Italian Liver Cancer (ITA.LI.CA) database, 512 patients receiving frontline LR for single HCC ≤5 cm were retrieved. Incidence and predictors of recurrence beyond Milan criteria (MC) and up‐to‐seven criteria were compared between patients with HCC <4 and ≥4 cm. Results: During a median follow‐up of 4.2 years, the overall recurrence rate was 55.9%. In the ≥4 cm group, a significantly higher proportion of patients recurred beyond MC at first recurrence (28.9% vs. 14.1%; p < 0.001) and overall (44.4% vs. 25.2%; p < 0.001). Similar results were found considering recurrence beyond up‐to‐seven criteria. Compared to those with larger tumours, patients with HCC <4 cm had a longer recurrence‐free survival and overall survival. HCC size ≥4 cm and high alpha‐fetoprotein (AFP) level at the time of LR were independent predictors of recurrence beyond MC (and up‐to‐seven criteria). In the subgroup of patients with available histologic information (n = 354), microvascular invasion and microsatellite lesions were identified as additional independent risk factors for non‐transplantable recurrence. Conclusions: Despite the high recurrence rate, LR for single HCC ≤5 cm offers excellent long‐term survival. Non‐transplantable recurrence is predicted by HCC size and AFP levels, among pre‐operatively available variables. High‐risk patients could be considered for frontline LT or listed for transplantation even before recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
- Author
-
Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica, Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, and Romagnoli, Veronica
- Subjects
Liver Cancer ,Pre-TACE-Predict model ,medicine.medical_specialty ,business.industry ,Trans-arterial chemoembolization ,Pharmaceutical Science ,hepatocellular carcinoma ,medicine.disease ,Gastroenterology ,Complementary and alternative medicine ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Pharmacology (medical) ,Trans arterial chemoembolization ,business - Abstract
Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.
- Published
- 2021
- Full Text
- View/download PDF
33. Infectious Pneumonia and Lung Ultrasound: A Review
- Author
-
Boccatonda, Andrea, primary, Cocco, Giulio, additional, D’Ardes, Damiano, additional, Delli Pizzi, Andrea, additional, Vidili, Gianpaolo, additional, De Molo, Chiara, additional, Vicari, Susanna, additional, Serra, Carla, additional, Cipollone, Francesco, additional, Schiavone, Cosima, additional, and Guagnano, Maria Teresa, additional
- Published
- 2023
- Full Text
- View/download PDF
34. Gastrointestinal Ultrasound in Emergency Setting
- Author
-
Boccatonda, Andrea, primary, D’Ardes, Damiano, additional, Tallarico, Viola, additional, Vicari, Susanna, additional, Bartoli, Elena, additional, Vidili, Gianpaolo, additional, Guagnano, Maria Teresa, additional, Cocco, Giulio, additional, Cipollone, Francesco, additional, Schiavone, Cosima, additional, and Accogli, Esterita, additional
- Published
- 2023
- Full Text
- View/download PDF
35. An ultrasound-based approach to jaundice from diagnosis to treatment
- Author
-
Vidili, Gianpaolo, primary, Arru, Marco, additional, Solinas, Beatrice, additional, and Turilli, Davide, additional
- Published
- 2022
- Full Text
- View/download PDF
36. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
- Author
-
Giannini, Edoardo G., primary, Pieri, Giulia, additional, Labanca, Sara, additional, Plaz Torres, Maria Corina, additional, Gasbarrini, Antonio, additional, Biasini, Elisabetta, additional, Campani, Claudia, additional, Cazzagon, Nora, additional, Foschi, Francesco Giuseppe, additional, Mega, Andrea, additional, Masotto, Alberto, additional, Raimondo, Giovanni, additional, Rapaccini, Gian Ludovico, additional, Sacco, Rodolfo, additional, Caturelli, Eugenio, additional, Guarino, Maria, additional, Tovoli, Francesco, additional, Vidili, Gianpaolo, additional, Brunetto, Maurizia Rossana, additional, Nardone, Gerardo, additional, Svegliati-Baroni, Gianluca, additional, Magalotti, Donatella, additional, Azzaroli, Francesco, additional, Cabibbo, Giuseppe, additional, Di Marco, Maria, additional, Sangiovanni, Angelo, additional, Trevisani, Franco, additional, Biselli, Maurizio, additional, Caraceni, Paolo, additional, Gramenzi, Annagiulia, additional, Benevento, Francesca, additional, Granito, Alessandro, additional, Muratori, Luca, additional, Piscaglia, Fabio, additional, Bertellini, Federica, additional, Farinati, Fabio, additional, Palano, Giorgio, additional, Pelizzaro, Filippo, additional, Penzo, Barbara, additional, Pinto, Elisa, additional, Allegrini, Gloria, additional, Cammà, Calogero, additional, Celsa, Ciro, additional, Giuffrida, Paolo, additional, Stornello, Caterina, additional, Grova, Mauro, additional, Giacchetto, Carmelo Marco, additional, Rancatore, Gabriele, additional, Grassini, Maria Vittoria, additional, Adotti, Valentina, additional, Gitto, Stefano, additional, Marra, Fabio, additional, Rosi, Martina, additional, Bevilacqua, Vittoria, additional, Borghi, Alberto, additional, Gardini, Andrea Casadei, additional, Conti, Fabio, additional, Napoli, Lucia, additional, Domenicali, Marco, additional, Migliano, Maria Teresa, additional, de Matthaeis, Nicoletta, additional, Ponziani, Francesca Romana, additional, Olivani, Andrea, additional, Missale, Gabriele, additional, Cossiga, Valentina, additional, Capasso, Mario, additional, Morisco, Filomena, additional, Cela, Ester Marina, additional, Facciorusso, Antonio, additional, Lauria, Valentina, additional, Ghittoni, Giorgia, additional, Pelecca, Giorgio, additional, Chegai, Fabrizio, additional, Coratella, Fabio, additional, Ortenzi, Mariano, additional, Dell'Isola, Serena, additional, Franzè, Maria Stella, additional, Saitta, Carlo, additional, Sauchella, Assunta, additional, Dajti, Elton, additional, Ravaioli, Federico, additional, Oliveri, Filippo, additional, Ricco, Gabriele, additional, Romagnoli, Veronica, additional, Inno, Alessandro, additional, Marchetti, Fabiana, additional, Coccoli, Pietro, additional, Malerba, Antonio, additional, Cappelli, Alberta, additional, Golfieri, Rita, additional, Mosconi, Cristina, additional, and Renzulli, Matteo, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis
- Author
-
Ageno, Walter, Dentali, Francesco, De Stefano, Valerio, Barco, Stefano, Lerede, Teresa, Bazzan, Mario, Piana, Antonietta, Santoro, Rita, Duce, Rita, Poli, Daniela, Martinelli, Ida, Siragusa, Sergio, Barillari, Giovanni, Cattaneo, Marco, Vidili, Gianpaolo, Carpenedo, Monica, Rancan, Elena, Giaretta, Ilaria, and Tosetto, Alberto
- Published
- 2014
- Full Text
- View/download PDF
38. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis
- Author
-
Vidili, Gianpaolo, primary, Arru, Marco, additional, Solinas, Giuliana, additional, Calvisi, Diego Francesco, additional, Meloni, Pierluigi, additional, Sauchella, Assunta, additional, Turilli, Davide, additional, Fabio, Claudio, additional, Cossu, Antonio, additional, Madeddu, Giordano, additional, Babudieri, Sergio, additional, Zocco, Maria Assunta, additional, Iannetti, Giovanni, additional, Di Lembo, Enza, additional, Delitala, Alessandro Palmerio, additional, and Manetti, Roberto, additional
- Published
- 2022
- Full Text
- View/download PDF
39. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
- Author
-
Izquierdo-Sánchez, Laura, primary, Lamarca, Angela, additional, La Casta, Adelaida, additional, Buettner, Stefan, additional, Utpatel, Kirsten, additional, Klümpen, Heinz-Josef, additional, Adeva, Jorge, additional, Vogel, Arndt, additional, Lleo, Ana, additional, Fabris, Luca, additional, Ponz-Sarvise, Mariano, additional, Raffaele, Brustia, additional, Cardinale, Vincenzo, additional, Braconi, Chiara, additional, Vidili, Gianpaolo, additional, Jamieson, Nigel B., additional, Macias, Rocio IR, additional, Jonas, Philipp, additional, Marzioni, Marco, additional, Hołówko, Wacław, additional, Folseraas, Trine, additional, Kupcinskas, Juozas, additional, Sparchez, Zeno, additional, Krawczyk, Marcin, additional, Krupa, Łukasz, additional, Scripcariu, Viorel, additional, Grazi, Gianluca, additional, Landa-Magdalena, Ana, additional, Ijzermans, Jan, additional, Evert, Katja, additional, Erdmann, Joris, additional, López-López, Flora, additional, Saborowski, Anna, additional, Scheiter, Alexander, additional, Santos-Laso, Alvaro, additional, Carpino, Guido, additional, Andersen, Jesper, additional, Marin, Jose, additional, Alvaro, Domenico, additional, Bujanda, Luis, additional, Forner, Alejandro, additional, Valle, Juan, additional, Koerkamp, Bas Groot, additional, and Banales, Jesus Maria, additional
- Published
- 2022
- Full Text
- View/download PDF
40. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
- Author
-
Medicina, Medikuntza, Izquierdo Sánchez, Laura, Lamarca, Angela, La Casta, Adelaida, Buettner, Stefan, Utpatel, Kirsten, Klümpen, Heinz-Josef, Adeva, Jorge, Vogel, Arndt, Lleo, Ana, Fabris, Luca, Ponz-Sarvise, Mariano, Brustia, Raffaele, Cardinale, Vincenzo, Braconi, Chiara, Vidili, Gianpaolo, Jamieson, Nigel B., Macias, Rocio IR., Jonas, Jan Philipp, Marzioni, Marco, Hołówko, Wacław, Folseraas, Trine, Kupčinskas, Juozas, Sparchez, Zeno, Krawczyk, Marcin, Krupa, Łukasz, Scripcariu, Viorel, Grazi, Gian Luca, Landa Magdalena, Ana, Ijzermans, Jan NM., Evert, Katja, Erdmann, Joris I., López-López, Flora, Saborowski, Anna, Scheiter, Alexander, Santos Laso, Álvaro, Carpino, Guido, Andersen, Jesper B., Marin, Jose JG., Alvaro, Domenico, Bujanda Fernández de Pierola, Luis, Forner, Alejandro, Valle, Juan W., Koerkamp, Bas Groot, Bañales Asurmendi, Jesús María, Medicina, Medikuntza, Izquierdo Sánchez, Laura, Lamarca, Angela, La Casta, Adelaida, Buettner, Stefan, Utpatel, Kirsten, Klümpen, Heinz-Josef, Adeva, Jorge, Vogel, Arndt, Lleo, Ana, Fabris, Luca, Ponz-Sarvise, Mariano, Brustia, Raffaele, Cardinale, Vincenzo, Braconi, Chiara, Vidili, Gianpaolo, Jamieson, Nigel B., Macias, Rocio IR., Jonas, Jan Philipp, Marzioni, Marco, Hołówko, Wacław, Folseraas, Trine, Kupčinskas, Juozas, Sparchez, Zeno, Krawczyk, Marcin, Krupa, Łukasz, Scripcariu, Viorel, Grazi, Gian Luca, Landa Magdalena, Ana, Ijzermans, Jan NM., Evert, Katja, Erdmann, Joris I., López-López, Flora, Saborowski, Anna, Scheiter, Alexander, Santos Laso, Álvaro, Carpino, Guido, Andersen, Jesper B., Marin, Jose JG., Alvaro, Domenico, Bujanda Fernández de Pierola, Luis, Forner, Alejandro, Valle, Juan W., Koerkamp, Bas Groot, and Bañales Asurmendi, Jesús María
- Abstract
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence and related mortality is increasing. This study investigates the clinical course of CCA and subtypes (intrahepatic [iCCA], perihilar [pCCA], and distal [dCCA]) in a pan-European cohort. Methods: The ENSCCA Registry is a multicenter observational study. Patients were included if they had a histologically proven diagnosis of CCA between 2010-2019. Demographic, histomorphological, biochemical, and clinical studies were performed. Results: Overall, 2,234 patients were enrolled (male/female=1.29). iCCA (n = 1,243) was associated with overweight/ obesity and chronic liver diseases involving cirrhosis and/or viral hepatitis; pCCA (n = 592) with primary sclerosing cholangitis; and dCCA (n = 399) with choledocholithiasis. At diagnosis, 42.2% of patients had local disease, 29.4% locally advanced disease (LAD), and 28.4% metastatic disease (MD). Serum CEA and CA199 showed low diagnostic sensitivity, but their concomitant elevation was associated with increased risk of presenting with LAD (odds ratio 2.16; 95% CI 1.43-3.27) or MD (odds ratio 5.88; 95% CI 3.69-9.25). Patients undergoing resection (50.3%) had the best outcomes, particularly with negative-resection margin (R0) (median overall survival [mOS] = 45.1 months); however, margin involvement (R1) (hazard ratio 1.92; 95% CI 1.53-2.41; mOS = 24.7 months) and lymph node invasion (hazard ratio 2.13; 95% CI 1.55-2.94; mOS = 23.3 months) compromised prognosis. Among patients with unresectable disease (49.6%), the mOS was 10.6 months for those receiving active palliative therapies, mostly chemotherapy (26.2%), and 4.0 months for those receiving best supportive care (20.6%). iCCAs were associated with worse outcomes than p/dCCAs. ECOG performance status, MD and CA19-9 were independent prognostic factors. Conclusion: CCA is frequently diagnosed at an advanced stage, a proportion of patients fail to receive cancer-specific therap
- Published
- 2022
41. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
- Author
-
Pelizzaro, Filippo, Haxhi, Selion, Penzo, Barbara, Vitale, Alessandro, Giannini, Edoardo G, Sansone, Vito, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Magalotti, Donatella, Sacco, Rodolfo, Celsa, Ciro, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Pelizzaro, Filippo, Haxhi, Selion, Penzo, Barbara, Vitale, Alessandro, Giannini, Edoardo G, Sansone, Vito, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Magalotti, Donatella, Sacco, Rodolfo, Celsa, Ciro, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
BackgroundTransarterial chemoembolization (TACE) is one of the most frequently applied treatments for hepatocellular carcinoma (HCC) worldwide. In this study, we aimed at evaluating whether and how TACE application and repetition, as well as the related outcome, have changed over the last three decades in Italy. MethodsData of 7,184 patients with HCC were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. Patients were divided according to the period of diagnosis in six cohorts: P1 (1988-1993), P2 (1994-1998), P3 (1999-2004), P4 (2005-2009), P5 (2010-2014), and P6 (2015-2019). All the analyses were repeated in the overall patient population and in Barcelona Clinic Liver Cancer (BCLC) B patients, who are the subgroup of HCC patients originally supposed to receive TACE according to guidelines. TACE was defined as either the first or the main (more effective) treatment. ResultsThe proportion of patients receiving TACE as first or main therapy declined over time, and less than 50% of BCLC B patients were treated with chemoembolization from P3 onward. Conversely, TACE was widely used even outside the intermediate stage. Survival of TACE-treated patients progressively increased from P1 to P6. Although TACE was performed only once in the majority of patients, there was an increasing proportion of those receiving 2 or >= 3 treatments sessions over time. The overall survival (OS) of patients undergoing repeated treatments was significantly higher compared to those managed with a single TACE (median OS 40.0 vs. 65.0 vs. 71.8 months in 1, 2, and >= 3 TACE groups, respectively; p < 0.0001). However, after a first-line TACE, the adoption of curative therapies provided longer survival than repeating TACE (83.0 vs. 42.0 months; p < 0.0001), which in turn was associated with better outcomes compared to systemic therapies or best supportive care (BSC). ConclusionsDespite a decline in the percentage of treated patients over time, TACE has still an important rol
- Published
- 2022
42. Surveillance for hepatocellular carcinoma with a 3-months interval in 'extremely high-risk' patients does not further improve survival
- Author
-
Pelizzaro, Filippo, Peserico, Giulia, D'Elia, Marco, Cazzagon, Nora, Russo, Francesco Paolo, Vitale, Alessandro, Giannini, Edoardo G, Piccinnu, Manuela, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Pelizzaro, Filippo, Peserico, Giulia, D'Elia, Marco, Cazzagon, Nora, Russo, Francesco Paolo, Vitale, Alessandro, Giannini, Edoardo G, Piccinnu, Manuela, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
Background: An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC).Aims: We compared the 3-and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival.Methods: Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching.Results: The 3-months surveillance interval neither reduced the share of patients diagnosed outside the Milano criteria, nor increased their probability to receive curative treatments. The median survival of 6MS patients (55.0 months [45.9-64.0]) was not significantly different from the observed (47.0 months [35.0-58.9]; p = 0.43) and adjusted (44.9 months [33.4-56.4]; p = 0.30) survival of 3MS patients. A propensity score analysis confirmed the absence of a survival advantage for 3MS patients.Conclusions: A tightening of surveillance schedule does not increase the diagnosis of early-stage tumors, the feasibility of curative treatments and the survival. Therefore, we should maintain the 6-months interval in the surveillance of viral cirrhotics. (C) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2022
43. Cholangiocarcinoma landscape in Europe:Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
- Author
-
Izquierdo-Sanchez, Laura, Lamarca, Angela, La Casta, Adelaida, Buettner, Stefan, Utpatel, Kirsten, Klümpen, Heinz Josef, Adeva, Jorge, Vogel, Arndt, Lleo, Ana, Fabris, Luca, Ponz-Sarvise, Mariano, Brustia, Raffaele, Cardinale, Vincenzo, Braconi, Chiara, Vidili, Gianpaolo, Jamieson, Nigel B., Macias, Rocio IR, Jonas, Jan Philipp, Marzioni, Marco, Hołówko, Wacław, Folseraas, Trine, Kupčinskas, Juozas, Sparchez, Zeno, Krawczyk, Marcin, Krupa, Łukasz, Scripcariu, Viorel, Grazi, Gian Luca, Landa-Magdalena, Ana, IJzermans, Jan N.M., Evert, Katja, Erdmann, Joris I., López-López, Flora, Saborowski, Anna, Scheiter, Alexander, Santos-Laso, Alvaro, Carpino, Guido, Andersen, Jesper B., Marin, Jose JG, Alvaro, Domenico, Bujanda, Luis, Forner, Alejandro, Valle, Juan W., Koerkamp, Bas Groot, Banales, Jesus M., Izquierdo-Sanchez, Laura, Lamarca, Angela, La Casta, Adelaida, Buettner, Stefan, Utpatel, Kirsten, Klümpen, Heinz Josef, Adeva, Jorge, Vogel, Arndt, Lleo, Ana, Fabris, Luca, Ponz-Sarvise, Mariano, Brustia, Raffaele, Cardinale, Vincenzo, Braconi, Chiara, Vidili, Gianpaolo, Jamieson, Nigel B., Macias, Rocio IR, Jonas, Jan Philipp, Marzioni, Marco, Hołówko, Wacław, Folseraas, Trine, Kupčinskas, Juozas, Sparchez, Zeno, Krawczyk, Marcin, Krupa, Łukasz, Scripcariu, Viorel, Grazi, Gian Luca, Landa-Magdalena, Ana, IJzermans, Jan N.M., Evert, Katja, Erdmann, Joris I., López-López, Flora, Saborowski, Anna, Scheiter, Alexander, Santos-Laso, Alvaro, Carpino, Guido, Andersen, Jesper B., Marin, Jose JG, Alvaro, Domenico, Bujanda, Luis, Forner, Alejandro, Valle, Juan W., Koerkamp, Bas Groot, and Banales, Jesus M.
- Abstract
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence and related mortality is increasing. This study investigates the clinical course of CCA and subtypes (intrahepatic [iCCA], perihilar [pCCA], and distal [dCCA]) in a pan-European cohort. Methods: The ENSCCA Registry is a multicenter observational study. Patients were included if they had a histologically proven diagnosis of CCA between 2010-2019. Demographic, histomorphological, biochemical, and clinical studies were performed. Results: Overall, 2,234 patients were enrolled (male/female=1.29). iCCA (n = 1,243) was associated with overweight/obesity and chronic liver diseases involving cirrhosis and/or viral hepatitis; pCCA (n = 592) with primary sclerosing cholangitis; and dCCA (n = 399) with choledocholithiasis. At diagnosis, 42.2% of patients had local disease, 29.4% locally advanced disease (LAD), and 28.4% metastatic disease (MD). Serum CEA and CA19-9 showed low diagnostic sensitivity, but their concomitant elevation was associated with increased risk of presenting with LAD (odds ratio 2.16; 95% CI 1.43-3.27) or MD (odds ratio 5.88; 95% CI 3.69-9.25). Patients undergoing resection (50.3%) had the best outcomes, particularly with negative-resection margin (R0) (median overall survival [mOS] = 45.1 months); however, margin involvement (R1) (hazard ratio 1.92; 95% CI 1.53-2.41; mOS = 24.7 months) and lymph node invasion (hazard ratio 2.13; 95% CI 1.55-2.94; mOS = 23.3 months) compromised prognosis. Among patients with unresectable disease (49.6%), the mOS was 10.6 months for those receiving active palliative therapies, mostly chemotherapy (26.2%), and 4.0 months for those receiving best supportive care (20.6%). iCCAs were associated with worse outcomes than p/dCCAs. ECOG performance status, MD and CA19-9 were independent prognostic factors. Conclusion: CCA is frequently diagnosed at an advanced stage, a proportion of patients fai
- Published
- 2022
44. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
- Author
-
Giannini, Edoardo G, Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria Teresa, Sangiovanni, Angelo, Trevisani, Franco, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Giannini, Edoardo G, Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria Teresa, Sangiovanni, Angelo, Trevisani, Franco, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), and Di Marco, Maria
- Abstract
Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 vs 4.0 cm, P = 0.007). Curative treatment, feasible in 50.0% of patients, was associated with improved survival compared to palliative and supportive care (42 vs 33 vs 6 months, P<0.0001). Surveillance was associated with a non-significant improved survival (36 vs 23 months), likely due to similar rate of curative treatment in patients under (51.4%) and outside surveillance (42.6%). Conclusions: PBC patients with HCC are often elderly males with well-preserved liver function. Feasibility of curative treatment is high and associated with improved prognosis. Description of these patients may help focus surveillance to identify earlier tumours, increase their curability, and improve prognosis.
- Published
- 2022
45. Functionalized multiwalled carbon nanotubes as ultrasound contrast agents
- Author
-
Delogu, Lucia Gemma, Vidili, Gianpaolo, Venturelli, Enrica, Ménard-Moyon, Cécilia, Zoroddu, Maria Antonietta, Pilo, Giovannantonio, Nicolussi, Paola, Ligios, Ciriaco, Bedognetti, Davide, Sgarrella, Francesco, Manetti, Roberto, and Bianco, Alberto
- Published
- 2012
46. Asymptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications
- Author
-
Loffredo, Lorenzo, primary, Vidili, Gianpaolo, additional, Sciacqua, Angela, additional, Cogliati, Chiara, additional, Giulio, Rosella Di, additional, Bernardini, Sciaila, additional, Ciacci, Paolo, additional, Pietrangelo, Antonello, additional, Orlando, Federica, additional, Paraninfi, Aurora, additional, Boddi, Maria, additional, Minno, Giovanni Di, additional, Falsetti, Lorenzo, additional, Lodigiani, Corrado, additional, Santoliquido, Angelo, additional, Ettorre, Evaristo, additional, Pignatelli, Pasquale, additional, Arezzo, Maria Felice, additional, Harenberg, Job, additional, and Violi, Francesco, additional
- Published
- 2022
- Full Text
- View/download PDF
47. Role of Lung Ultrasound in the Management of Patients with Suspected SARS-CoV-2 Infection in the Emergency Department
- Author
-
Boccatonda, Andrea, primary, Grignaschi, Alice, additional, Lanotte, Antonella Maria Grazia, additional, Cocco, Giulio, additional, Vidili, Gianpaolo, additional, Giostra, Fabrizio, additional, and Schiavone, Cosima, additional
- Published
- 2022
- Full Text
- View/download PDF
48. Non‐invasive tools for the prediction of esophageal varices in cirrhosis: Can advanced ultrasound techniques spare endoscopy?
- Author
-
Vidili, Gianpaolo, primary and Arru, Marco, additional
- Published
- 2022
- Full Text
- View/download PDF
49. Monofocal hepatocellular carcinoma: How much does size matter?
- Author
-
Pelizzaro, Filippo, Penzo, Barbara, Peserico, Giulia, Imondi, Angela, Sartori, Anna, Vitale, Alessandro, Cillo, Umberto, Giannini, Edoardo G., Forgione, Antonella, Ludovico Rapaccini, Gian, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Giuseppe Foschi, Francesco, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Biselli, Maurizio, Caraceni, Paolo, Garuti, Francesca, Gramenzi, Annagiulia, Neri, Andrea, Santi, Valentina, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Sansone, Vito, Tovoli, Francesco, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Sammarco, Ambra, Cela, Ester Marina, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, Moscatelli, Alessandro, Pellegatta, Gaia, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Missale, Gabriele, Inno, Alessandro, Marchetti, Fabiana, Busacca, Anita, Cammà, Calogero, Martino, Vincenzo Di, Emanuele Maria Rizzo, Giacomo, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Bevilacqua, Vittoria, Borghi, Alberto, Casadei Gardini, Andrea, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Mirici, Federica, Campani, Claudia, Bonaventura, Chiara Di, Gitto, Stefano, Coccoli, Pietro, Malerba, Antonio, Guarino, Maria, Brunetto, Maurizia, Romagnoli, Veronica, Pelizzaro, Filippo, Penzo, Barbara, Peserico, Giulia, Imondi, Angela, Sartori, Anna, Vitale, Alessandro, Cillo, Umberto, Giannini, Edoardo G., Forgione, Antonella, Ludovico Rapaccini, Gian, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Giuseppe Foschi, Francesco, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Biselli, Maurizio, Caraceni, Paolo, Garuti, Francesca, Gramenzi, Annagiulia, Neri, Andrea, Santi, Valentina, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Sansone, Vito, Tovoli, Francesco, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Sammarco, Ambra, Cela, Ester Marina, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, Moscatelli, Alessandro, Pellegatta, Gaia, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Missale, Gabriele, Inno, Alessandro, Marchetti, Fabiana, Busacca, Anita, Cammà, Calogero, Martino, Vincenzo Di, Emanuele Maria Rizzo, Giacomo, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Bevilacqua, Vittoria, Borghi, Alberto, Casadei Gardini, Andrea, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Mirici, Federica, Campani, Claudia, Bonaventura, Chiara Di, Gitto, Stefano, Coccoli, Pietro, Malerba, Antonio, Guarino, Maria, Brunetto, Maurizia, Romagnoli, Veronica, Giannini, Edoardo G, Svegliati-Baroni, Gianluca, for the Italica, Group, Pelizzaro F., Penzo B., Peserico G., Imondi A., Sartori A., Vitale A., Cillo U., Giannini E.G., Forgione A., Ludovico Rapaccini G., Di Marco M., Caturelli E., Zoli M., Sacco R., Cabibbo G., Marra F., Mega A., Morisco F., Gasbarrini A., Svegliati-Baroni G., Giuseppe Foschi F., Olivani A., Masotto A., Nardone G., Raimondo G., Azzaroli F., Vidili G., Oliveri F., Trevisani F., Farinati F., Biselli M., Caraceni P., Garuti F., Gramenzi A., Neri A., Santi V., Granito A., Muratori L., Piscaglia F., Sansone V., Tovoli F., Dajti E., Marasco G., Ravaioli F., Cappelli A., Golfieri R., Mosconi C., Renzulli M., Sammarco A., Cela E.M., Facciorusso A., Cacciato V., Casagrande E., Moscatelli A., Pellegatta G., de Matthaeis N., Allegrini G., Lauria V., Ghittoni G., Pelecca G., Chegai F., Coratella F., Ortenzi M., Missale G., Inno A., Marchetti F., Busacca A., Qabibboz G., Camma C., Martino V.D., Emanuele Maria Rizzo G., Franze M.S., Saitta C., Sauchella A., Bevilacqua V., Borghi A., Casadei Gardini A., Conti F., Dall'Aglio A.C., Ercolani G., Mirici F., Campani C., Bonaventura C.D., Gitto S., Coccoli P., Malerba A., Guarino M., Brunetto M., Romagnoli V., Rapaccini, Gian Ludovico, and Foschi, Francesco Giuseppe
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Carcinoma, Hepatocellular ,Independent predictor ,Gastroenterology ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Hepatectomy ,Humans ,Staging system ,Neoplasm Staging ,Retrospective Studies ,Settore MED/12 - Gastroenterologia ,Hepatology ,treatment ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Liver Neoplasms ,bclc staging system ,monofocal hepatocellular carcinoma ,medicine.disease ,digestive system diseases ,Survival benefit ,Italy ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,liver resection ,prognosis ,030211 gastroenterology & hepatology ,business ,Liver cancer ,prognosi - Abstract
Background & Aims: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (>5cm) monofocal (HCC). Methods: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5cm; SEM-HCC), 163 patients with larger tumours (>5cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). Results: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0months; P 
- Published
- 2021
50. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
- Author
-
Pelizzaro, Filippo, primary, Haxhi, Selion, additional, Penzo, Barbara, additional, Vitale, Alessandro, additional, Giannini, Edoardo G., additional, Sansone, Vito, additional, Rapaccini, Gian Ludovico, additional, Di Marco, Maria, additional, Caturelli, Eugenio, additional, Magalotti, Donatella, additional, Sacco, Rodolfo, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Mega, Andrea, additional, Guarino, Maria, additional, Gasbarrini, Antonio, additional, Svegliati-Baroni, Gianluca, additional, Foschi, Francesco Giuseppe, additional, Olivani, Andrea, additional, Masotto, Alberto, additional, Nardone, Gerardo, additional, Raimondo, Giovanni, additional, Azzaroli, Francesco, additional, Vidili, Gianpaolo, additional, Brunetto, Maurizia Rossana, additional, Trevisani, Franco, additional, and Farinati, Fabio, additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.